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ABSTRACT
Adequate iron levels are essential for human health. However, iron overload can 
act as catalyst for the formation of free radicals, which may cause cancer. Cancer stem 
cells (CSCs), which maintain the hallmark stem cell characteristics of self-renewal and 
differentiation capacity, have been proposed as a driving force of tumorigenesis and 
metastases. In the present study, we investigated the role of iron in the proliferation 
and stemness of CSCs, using the miPS-LLCcm cell model. Although the anti-cancer 
agents fluorouracil and cisplatin suppressed the proliferation of miPS-LLCcm cells, 
these drugs did not alter the expression of stemness markers, including Nanog, SOX2, 
c-Myc, Oct3/4 and Klf4. In contrast, iron depletion by the iron chelators deferasirox 
and deferoxamine suppressed the proliferation of miPS-LLCcm cells and the expression 
of stemness markers. In an allograft model, deferasirox inhibited the growth of miPS-
LLCcm implants, which was associated with decreased expression of Nanog and Sox2. 
Altogether, iron appears to be crucial for the proliferation and maintenance of stemness 
of CSCs, and iron depletion may be a novel therapeutic strategy to target CSCs.
INTRODUCTION
According to the cancer stem cell (CSC) hypothesis, 
cancer tissues contain a low percentage of CSCs, which 
have the ability to differentiate and self-renew [1, 2]. 
CSCs are resistant to chemotherapy and radiation therapy, 
and are strongly implicated in relapse after treatment 
[3–5]. Although CSCs are considered to be important 
targets therapeutically, clinically effective CSC targeting 
strategies have not yet been established, at least partly 
because the low number and heterogeneity of CSCs in 
cancer tissues makes the evaluation of therapy difficult. 
Recently, a new CSC model was established from mouse 
induced pluripotent stem cells (miPS cells) at Okayama 
University [6]. This CSC model, referred to as miPS-
LLccm, was epigenetically induced from miPS cells by 
culturing in Lewis lung carcinoma conditioned medium 
for 4 weeks. miPS-LLCcm cells maintain expression 
of stemness markers, self-renew, and are pluripotent. 
miPS-LLCcm cells express Nanog-driven GFP in the 
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undifferentiated state, and also express the Yamanaka 
factors, Sox2, c-Myc, Oct3/4 and Klf4, which are 
characteristic of pluripotent stem cells, and are also CSC 
markers associated with tumorigenesis and resistance to 
therapy [7–10]. In vivo, miPS-LLCcm cells form tumors 
with a malignant phenotype including cytokeratin positive 
glands, high nuclear to cytoplasmic ratio, severe nuclear 
atypia, multiple pathological mitotic figures and hyper-
vascularization. Importantly, miPS-LLCcm cells have 
been used as an organ specific CSC model and for analysis 
of the CSC microenvironment [11, 12]. Although miPS-
LLCcm require induction in the context of organ specific 
CSC models, the system is a tractable and convenient 
approach for the evaluation of CSC marker expression and 
the efficacy of new CSC targeted therapies.
Iron plays a key role in critical cellular processes, 
such as energy production and DNA synthesis. Although 
adequate iron levels are essential for human health, 
iron overload is known to cause some types of cancer 
[13, 14]. We previously demonstrated that iron depletion 
had an anti-cancer effect on some types of malignancies 
[15–17], potentially reflecting an important role for iron 
in regulating the cancerous niche including stemness, 
and in turn suggesting that iron depletion may be an 
effective therapeutic option for cancer treatment. In this 
study, we studied the efficacy of iron depletion therapy 
targeting CSCs using the iron chelators, deferasirox and 
deferoxamine.
RESULTS
Iron supply enhances the proliferation of CSCs and 
the expression of stemness markers is maintained
We examined the in vitro effect of iron supply on 
CSC proliferation using the XTT cell proliferation assay. 
We simulated starvation conditions of low growth factor 
and iron concentrations using iron free DMEM plus 1% 
FCS. The normal conditions used were iron free DMEM 
plus 15% FCS. Under starvation conditions, transferrin 
(Holo) almost tripled CSC proliferation compared with 
control conditions (Figure 1A). Transferrin (Holo) did not 
enhance the proliferation of CSCs under normal conditions. 
Although there was a similar trend for differentiated 
murine cancer cells (Supplementary Figure 1B), murine 
normal fibroblasts were not affected (Supplementary 
Figure 1C). Flow cytometry and fluorescence microscopy 
showed that the GFP subset was not affected by iron supply 
(Figure 1B and 1C). The stemness markers, Nanog, Sox2, 
c-Myc, Oct3/4 and Klf4, were not affected by iron supply 
in western blot analysis (Figure 1D), suggesting that iron 
supply did not affect the stemness marker phenotype of the 
CSCs. The expression of Nanog was also unaffected by 
iron supply in miPS cells (Supplementary Figure 1D) and 
sphere formation and GFP fluorescence were unchanged 
(Supplementary Figure 1E). The expression of the 
transferrin receptor 1 (TfR1) and DMT1 were increased 
by iron supply in CSCs (Figure 1D and 1E). This result 
indicated that the CSCs responded to the iron supply 
by increasing iron uptake under starvation conditions. 
Together, iron supply enhanced the proliferation of CSCs, 
while the expression of stemness markers was maintained.
Iron chelators suppress the proliferation of CSCs 
We examined the in vitro antiproliferative activity 
of the iron chelators, deferasirox and DFO, against the 
miPS-LLCcm cells using XTT cell viability assay. CSCs 
were incubated with deferasirox and DFO in normal 
medium with 15% FCS for 48 hours. Deferasirox and DFO 
suppressed the proliferation of CSCs in a dose dependent 
manner (Figure 2A). Fluorescence microscopy also showed 
that deferasirox and DFO decreased the numbers of GFP 
positive cells in a dose dependent manner (Figure 2B). 
The iron chelators suppressed the proliferation of the 
differentiated mouse cancer cells, colon26 and 4T1, at 48 
hours (Supplementary Figure 2A). However, the chelators 
did not show strong antiproliferative activity against the 
normal fibroblast cell lines, MEF and NIH-3T3, at 48 
hours (Supplementary Figure 2B). IC50 analyses showed 
that deferasirox had a stronger antiproliferative effect than 
DFO (Table 1). These results indicated that the chelators 
had strong antiproliferative effects against CSCs and 
differentiated cancer cells, while normal fibroblasts were 
not affected.
Iron chelators suppress the proliferation of CSCs 
by induction of apoptosis and cell cycle arrest
We examined the mechanisms underlying the 
antiproliferative effects of the iron chelators on CSCs. 
The expression of cleaved PARP and cleaved caspase 
3 was increased by iron chelators in the western blot 
and densitometry analyses, which indicated that iron 
chelators induced apoptosis (Figure 3A and 3B). The 
induction of apoptosis was confirmed by TUNEL staining 
(Supplementary Figure 3A). The expression of cyclin D1, 
a key cell cycle control protein, was decreased by the iron 
chelators, which indicated that iron chelators induced 
cell cycle arrest in CSCs. Although the expression of 
cyclin A2 and cyclin E1 was also suppressed by DFO, 
Deferasirox did not significantly suppress their expression 
(Supplementary Figure 3B). These results indicated that 
iron chelators suppressed the proliferation of CSCs by 
induction of apoptosis and cell cycle arrest.
Iron chelators suppress the expression of 
stemness markers, including Nanog and 
Yamanaka factors, in the CSC model
Western blot analysis revealed that the iron chelators 
significantly suppressed the expression of stemness markers, 
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Figure 1: The additional effect of transferrin (Holo) on miPS-LLCcm cells in vitro. (A) Iron depletion and iron rich conditions 
were simulated by iron free medium and 1% or 15% FCS, respectively. Cell proliferation was measured using the XTT assay after incubation 
with transferrin for 48 hours at 37°C. Transferrin promoted the proliferation of miPS-LLCcm cells in iron depleted conditions (FCS1%), 
but not in iron rich conditions (FCS15%). Data are represented as average ± S.E.M. (n = 5). **: p < 0.01, ***: p < 0.001. (B) GFP subsets of 
miPS-LLCcm cells were measured by flow cytometry after incubation with transferrin for 48 hours at 37 °C. Transferrin did not affect the 
GFP subsets of miPS-LLCcm cells. Data are represented as average ± S.E.M. (n = 5). (C) Normal and fluorescence microscopy findings 
showed that transferrin promoted the proliferation of GFP positive and negative cells. (D) Cultured miPS-LLCcm cells were treated with 
different concentrations of transferrin for 48 hours in iron depleted conditions. Cells were then harvested and total protein was analyzed for 
expression of the indicated proteins. Transferrin did not affect the expression of stemness markers and promoted the expression of TfR1 
and DMT1. (E) Densitometry analysis of TfR1 and DMT1. The level of TfR1 and DMT1 expressed by non-treated cells was set at 100%. 
Data are represented as average ± S.E.M. (n = 3). *p < 0.05, **p < 0.01.
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Table 1: IC50 of deferasirox and DFO for miPS-LLCcm cells
Chelator IC50 (µM)
Deferasirox 42.0
DFO 47.0
IC50 values (µM) for deferasirox and DFO after a 48-hour, 37°C incubation using the miPS-LLCcm CSC model. Data 
represent the mean ± S.E.M. (n = 3).
Figure 2: The inhibitory effect of deferasirox and DFO on miPS-LLCcm cells in vitro. (A) Cultured miPS-LLCcm cells were 
treated with different concentrations of deferasirox and DFO for 48 hours and cell viability was then evaluated using the XTT assay. Cell 
viability in the absence of treatment was set at 100%. Results are means of 3 independent experiments. Data are represented as average ± 
S.E.M. (n = 5). ***p < 0.001. (B) Normal and fluorescence microscopy findings showed that numbers of GFP positive and negative cells 
were decreased in a dose dependent manner.
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Nanog and Oct3/4 (Figure 4A and 4B). Although the 
expression of Sox2, c-Myc, and Klf4 was also suppressed 
by deferasirox in a dose dependent manner, DFO did not 
significantly suppress these markers (Supplementary 
Figure 4). These results revealed that iron chelators 
suppressed the expression of CSC stemness markers, and 
the effect of deferasirox was stronger than that of DFO.
5-FU and cisplatin do not suppress the 
expression of stemness markers in CSCs
To address the effects of standard chemotherapy 
on the CSC model, we examined cell viability and the 
expression of stemness markers following treatment with 
5-FU and cisplatin. 5-FU and cisplatin suppressed the 
Figure 3: Western blot analysis of apoptosis and cell cycle related proteins in miPS-LLCcm cells. (A) Cultured miPS-
LLCcm cells were treated with different concentrations of deferasirox and DFO for 48 hours. Cells were then harvested and total protein 
was analyzed for expression of the indicated proteins. Deferasirox and DFO induced the apoptosis related markers, cleaved caspase 3 
and cleaved PARP, and decreased the cell cycle related marker, cyclin D1. (B) Densitometry analysis of the western blots also showed 
deferasirox and DFO significantly induced cleaved caspase 3 and cleaved PARP, and decreased cyclin D1 and cyclin E1. Data are represented 
as average ± S.E.M. (n = 3) *p < 0.05, **p < 0.01, ***p < 0.001.
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viability of CSCs in a dose dependent manner (Figure 5A), 
but did not suppress the expression of stemness markers 
(Figure 5B). GFP positive cells were also detected 
by fluorescence microscopy after treatment (data not 
shown) and the expression of GFP did not decrease 
(Supplementary Figure 4B). These results indicated that 
5-FU and cisplatin acted only on differentiated cells and 
not on cells expressing stemness markers, suggesting that 
the suppression of stemness markers is a unique function 
of iron chelators.
Iron chelators suppress tumor growth and 
expression of stemness markers
To address the suppression of proliferation and 
stemness markers in vivo, we employed a miPS-LLCcm 
CSC tumor allograft model using BALB/c nude mice. 
The chelators were administered directly according to 
clinical dose guidelines at 30 mg/kg for 5 days in a week. 
After 18 days of local treatment with the vehicle control 
(PBS) the tumor allografts reached an average volume 
Figure 4: Western blot analysis of stemness marker expression in miPS-LLCcm cells. (A) Cultured miPS-LLCcm cells were 
treated with different concentrations of deferasirox and DFO for 48 hours. Cells were then harvested and total protein was analyzed for the 
expression of indicated proteins. Deferasirox and DFO decreased the expression of stemness markers. (B) Densitometry analysis of the 
western blots also showed deferasirox and DFO significantly decreased the expression of the stemness markers, Nanog and Oct3/4. Data 
are represented as average ± S.E.M. (n = 3) *p < 0.05, **p < 0.01, ***p < 0.001.
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of 1270.82 ± 411.17 mm3. However, the iron chelators 
significantly decreased tumor growth (deferasirox 360.27 
± 148.84 mm3; DFO 502.53 ± 207.45 mm3, Figure 6A 
and 6B). Tumor weight was also significantly decreased 
in the iron chelator groups (tumor weight: control vs 
deferasirox vs DFO: 1250 ± 300 mg vs 600 ± 180 mg vs 
400 ± 50 mg) (Figure 6C). The body weights of treated 
mice were not significantly different to controls, which 
indicated that iron chelators did not induce serious side 
effects (Supplementary Figure 5A). To examine the 
suppression of stemness markers, tumors were collected 
for immunohistochemistry. Deferasirox and DFO 
suppressed the expression of GFP and stemness markers, 
including Nanog, Sox2, c-Myc, Oct3/4 (Figure 6D and 
Supplementary Figure 5B). The blue spots of berlin blue 
iron staining were detectable only in the control group, 
which indicated that iron in the tumor was decreased 
by deferasirox and DFO. These results indicated that 
iron chelators suppressed CSC tumor growth and the 
expression of stemness markers in vivo.
DISCUSSION
The expression of stemness markers is reported to 
be linked to increased malignant potential [10]. Although 
CSCs are thought to be associated with resistance to 
chemotherapy, the lack of a suitable study model to 
comprehensively address this question [18–20] has 
Figure 5: XTT cell proliferation assay and western blot analysis of miPS-LLCcm cells following 5-FU and cisplatin 
treatment. (A) Cultured miPS-LLCcm cells were treated with different concentrations of 5-FU and cisplatin for 48 hours, and cell 
viability was then evaluated using the XTT assay. 5-FU and cisplatin suppressed the proliferation of miPS-LLCcm cells in a dose dependent 
manner. Cell viability in the absence of treatment was set at 100%. Results are means of 3 independent experiments. Data are represented as 
average ± S.E.M. (n = 5). ***p < 0.001. (B) Cultured miPS-LLCcm cells were treated with different concentrations of 5-FU and cisplatin for 
48 hours. Cells were then harvested and total protein was analyzed for expression of the indicated proteins. Western blot analysis showed 
that 5-FU and cisplatin did not suppress the expression of stemness markers.
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Figure 6: Iron chelators suppressed the growth of CSC tumor allografts and suppressed stemness marker expression. 
(A) miPS-LLCcm cells (1 × 106 per animal) were implanted subcutaneously into the right back flank of mice and treatment commenced 5 
days after tumor injection. Deferasirox and DFO (30 mg/kg locally, given by injection 5 days per week for 14 days) effectively inhibited 
the growth of miPS-LLCcm allografts in vivo. *p < 0.05, **p < 0.01. (B) Macroscopic images showed that tumors in both deferasirox and 
DFO groups were smaller than in the control group. (C) Tumor weight was significantly decreased in the deferasirox and DFO groups. 
Data are represented as average ± S.E.M. (n = 4). **p < 0.01. (D) Resected tumors were analyzed for Nanog and SOX2 expression by 
immunohistochemistry, and Fe3+ by Berlin blue staining. Nanog and SOX2 were suppressed in the deferasirox and DFO groups. Berlin blue 
staining was not detected in the deferasirox and DFO groups.
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compromised the development of CSC therapies. In this 
regard, our CSC model has some significant advantages 
over other models, including the stable expression of 
stemness markers, such as Nanog and the Yamanaka 
factors, and the regulation of stemness marker expression 
by puromycin selection. This latter feature in particular, 
facilitates more consistent experimental procedures for 
evaluating the efficacy of CSC targeted therapies.
Iron overload is known to induce some types of 
cancer [13, 14] and iron chelators were reported to have 
anti-cancer effects [21, 22]. We also reported that iron 
depletion had therapeutic potential for cancer treatment 
[15, 16] and not only suppressed the proliferation of 
cancer cells, but also their migration and invasion abilities 
[17]. These findings indicated that cancer cells use iron 
for many functions including proliferation and metastasis, 
and iron may also be critical for the maintenance of 
CSCs. Indeed, our studies showed that iron chelators 
have significant antiproliferative effects on both CSCs 
and differentiated cancer cells, but not normal fibroblasts, 
possibly because CSCs and differentiated cancer cells have 
a higher proliferative potential than normal fibroblasts.
The expression of stemness markers on CSCs was 
suppressed by iron chelators, which indicated that iron 
is linked to the maintenance of stemness. However, the 
relationship between stemness and iron metabolism is 
still unclear. Although both iron chelators increased the 
expression of TfR-1, the expression of DMT-1 remained 
unchanged (Supplementary Figure 3C and 3D). Increased 
expression of TfR-1 in response to iron depletion 
was anticipated. However, the reasons why DMT-1 
expression did not increase in parallel remain unclear. 
The expression of p53 tended to be increased by iron 
chelators (Supplementary Figure 3C), although not at 
higher concentrations of deferasirox (> 10 µM). Although 
the increase in p53 expression may reflect cell cycle arrest, 
further analysis is required to comprehensively address 
this possibility.
There are some reports that the inhibition of Nanog 
suppressed cancer cell proliferation and tumor growth 
[23, 24], and our results indicated that the role of Nanog 
might be similar in CSCs. 5-FU and cisplatin could not 
suppress the expression of stemness markers, which 
indicated that these standard anti-cancer drugs may not 
target CSCs. Thus, iron chelators may be an effective 
adjunct to standard chemotherapy. Moreover, iron chelators 
may reduce the development of resistance by suppression 
of the expression of stemness markers in the tumor. Further 
analysis of this phenomenon using orthotropic tumor 
models may help delineate the mechanisms underlying the 
development of resistance [25–27].
Deferasirox suppressed the expression of stemness 
markers more effectively than DFO. This is consistent with 
the suggestion that the chelation ability of deferasirox is 
stronger than DFO [28]. Although the therapeutic potential 
of PI3K/mTOR dual inhibitors for targeting CSCs has been 
reported [29, 30], this is the first description of an agent 
that can effectively suppress stemness marker expression, 
which may be a unique function of iron chelators.
Although iron chelators suppressed the expression 
of stemness markers, the mechanisms are currently 
unknown. This study may represent an important first step 
in the development of novel iron chelation based strategies 
for CSC therapy.
MATERIALS AND METHODS
Cell culture
Mouse induced pluripotent stem cells (miPS) were 
purchased from Riken Cell Bank (RIKEN BRC, Ibaraki, 
Japan). The Mouse Lewis lung carcinoma (LLC) cell line, 
mouse rectal cancer cell line (colon26) and mammary 
cancer cell line (4T1) were purchased from the American 
Type Culture Collection (ATCC, Manassas, VA, USA). We 
also used mouse fibroblast cell lines, MEF and NIH-3T3, 
that were obtained from the ATCC as representative of 
cells of a “normal” non-cancer phenotype. All cells were 
incubated at 37 °C in a humidified atmosphere containing 
5% CO2. miPS-LLCcm cells were epigenetically induced 
from miPS cells by culturing in Lewis lung carcinoma 
conditioned medium for 4 weeks [6, 11]. Cell culture 
dishes and multi-well plates for miPS-LLCcm culture 
were coated with 0.1% gelatin solution for 30 min at 37°C. 
miPS-LLCcm cells were maintained in DMEM containing 
15% FCS, 0.1 mM NEAA, 2 mM L-Glutamine, 0.1 mM 
2-mercaptoethanol, 50 U/ml penicillin and 50 U/ml 
streptomycin. Colon26, 4T1 MEF and NIH-3T3 cells 
were maintained in DMEM containing 10% FCS, 50 U/ml 
penicillin and 50 U/ml streptomycin.
Puromycin selection
miPS-LLCcm cultures contain GFP positive and 
GFP negative cells. Nanog driven GFP cells carry the 
puromycin-resistance gene facilitating the selection of 
miPS-LLCcm CSCs by puromycin resistance. Puromycin 
(puromycin dihydrochloride, catalog no. p8833, Sigma-
Aldrich, St. Louis, MO, USA) was dissolved in distilled 
water at a stock concentration of 1 μg/µl and added to the 
miPS-LLCcm medium at a final concentration of 1 μg/
ml. After puromycin selection, GFP positive cells were 
purified to almost 90% homogeneity (Supplementary 
Figure 1A). This approach was used to purify CSCs (GFP 
positive cells) for all experiments. Experiments were 
performed when the cultures were approximately 80% 
confluent after puromycin selection.
Holo-transferrin
Human Transferrin (Holo) (catalog no. 208–18971, 
Wako Pure Chemical Industries, Osaka, Japan) was dissolved 
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in distilled water at a stock concentration of 1 µg/µl and used 
as an iron supplement. Transferrin (Holo) was dissolved in 
distilled water at indicated concentrations.
Iron chelators
Deferasirox (EXJADE) and Deferoxamine (DFO, 
Desferal) were obtained from Novartis Pharma (Tokyo, Japan). 
For in vitro studies, DFO was dissolved in distilled water at a 
stock concentration of 50 mM. Deferasirox was dissolved in 
100% DMSO (Sigma-Aldrich) at a stock concentration of 50 
mM. DFO and deferasirox were dissolved in distilled water at 
indicated concentrations and directly injected.
Chemotherapeutic agents
5-fluorouracil (5-FU) was purchased from Kyowa 
Kirin (Tokyo, Japan), and dissolved in distilled water. 
Cisplatin (Randa) was purchased from Nippon Kayaku 
(Tokyo, Japan) and dissolved in PBS.
Cell proliferation assay
The XTT assay (Cell proliferation kit II, Roche 
Mannheim, Germany) was used to assess cell proliferation. 
We simulated iron depletion conditions using iron free DMEM 
plus 1% fetal calf serum (FCS), and iron rich conditions using 
iron free DMEM plus 15% FCS. The cells were incubated with 
holo-transferrin with 1% or 15% FCS and iron free DMEM for 
48 hours. The cells were incubated with deferasirox and DFO 
for 48 hours at 37°C in iron free medium plus 1% or 15% FCS. 
All experiments used 96-well plates and each experiment was 
repeated at least 3 times. Optical densities were measured at 
450 nm and 690 nm. We seeded the cells as follows; miPS-
LLCcm (1.0 × 104/well), 4T1 and colon26 (3.0 × 103/well), 
MEFs and NIH-3T3 (1.0 × 104/well).
Flow cytometry
GFP subsets of miPS-LLCcm cells were analyzed 
by flow cytometry (FACSArray, Becton Dickinson, 
Franklin Lakes, NJ, USA) using standard techniques.
Sphere formation assay
Single cells were plated into ultra-low attached 96-
well plates (Corning Costar, Sigma-Aldrich) at a density 
of 2.5 × 104 cells/ml. Cells were grown in serum-free 
miPS medium without leukemia inhibitory factor, and 
incubated for 72 hr.
Western blotting
Protein was extracted from whole cells after 48 
hours of incubation with medium and transferrin (Holo) 
or iron chelators. The concentrations of extracted protein 
were measured using standard protocols. Cells were lysed 
using cell lysis buffer (50 mmol/L Tris-HCl (pH7.4), 30 
mmol/L NaCl, and 1% Triton X-100) containing protease 
inhibitors (cOmplete Mini, Roche Diagnostics GmbH, 
Basel, Switzerland). Equal amounts of total cellular 
proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred 
electrophoretically to polyvinylidene difluoride filter 
membranes (GE Healthcare UK Ltd, Buckinghamshire, 
UK). Protein samples (40 μg/lane) were separated on 8% 
or 12% Tris-acrylamide gels and transferred to PVDF 
membranes (GE Healthcare Life Sciences) according to the 
manufacturer’s protocol. The following primary antibodies 
were used: rabbit polyclonal anti-Nanog antibody (catalog 
no. ab80892; Abcam, Cambridge, MA, USA), rabbit anti-
mouse SOX2 antibody (catalog no. ab97959, Abcam), rat 
anti-mouse Oct3/4 antibody (catalog no. MAB1759; R&D 
systems, Minneapolis, MN, USA), rabbit anti-mouse c-Myc 
antibody (catalog no. ab32072; Abcam), rabbit anti-mouse 
Klf4 antibody (catalog no. ab72543, Abcam), rabbit GFP 
polyclonal antibody (catalog no. 2956; Cell Signaling, 
Danvers, MA, USA), rabbit anti transferrin receptor 
antibody (catalog no. ab84036; Abcam), mouse monoclonal 
anti-β-actin antibody (catalog no.A5441, Sigma-Aldrich), 
rabbit polyclonal anti-PARP antibody (catalog no. 9542; 
Cell Signaling), rabbit polyclonal anti-cleaved caspase-3 
antibody (catalog no. 9664; Cell Signaling), rabbit 
polyclonal anti-caspase 3 antibody (catalog no. sc-7148; 
Santa Cruz, Dallas, TX, USA), rabbit monoclonal anti-
Cyclin A2 antibody (catalog no. ab181591, Abcam), 
rabbit monoclonal anti-Cyclin D1 antibody (catalog no. 
ab134175, Abcam), rabbit monoclonal anti-Cyclin E1 
antibody (catalog no. ab33911, Abcam), Rabbit polyclonal 
anti-p53 antibody (catalog no. ab131442, Abcam), Rabbit 
polyclonal anti- DMT1 antibody (catalog no. ab123085, 
Abcam). All primary antibodies were used at a 1:1000 
dilution. All secondary antibodies (GE Life Sciences) were 
used at a 1:2500 dilution. The membranes were incubated 
with primary antibodies overnight at 4 °C, followed by 
incubation with secondary antibodies. An ECL prime 
Western Blotting Detection Reagent (GE Healthcare 
UK Ltd.) was used to detect the peroxidase activity of 
secondary antibodies. All experiments were repeated at 
least 3 times. Membranes were probed for β-actin as a 
loading control, and all sample data values were normalized 
to the corresponding control data values. Densitometric 
analysis was performed using Image J software (NIH).
TUNEL staining
The induction of apoptosis was assessed by TUNEL 
assay using the MK500 in situ Apoptosis Detection Kit 
(TAKARA BIO, Shiga, Japan).
Tumor allograft model
All animal experiments were performed according 
to the Japanese Welfare and Management of Animals Act 
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and conducted in accordance with institutional guidelines 
at Shigei Medical Research Institute, Okayama, Japan. All 
animal experiments were approved by the Ethics Review 
Committee for Animal Experimentation of Shigei Medical 
Research Institute, Okayama, Japan (#150526–1). Female 
BALB/c (nu/nu) mice were purchased from the CLEA 
(Tokyo, Japan) and were housed in sterile conditions. 
Experiments started when the mice were 7 weeks of 
age. miPS-LLCcm tumor cells in culture were harvested 
and resuspended in a 1:1 ratio of PBS and Matrigel (BD 
Biosciences, San Jose, CA, USA). Viable miPS-LLCcm 
cells (1.0 × 106) were injected into the right back flanks 
of the mice subcutaneously. Tumor size was measured 
every 2 days. Deferasirox (30 mg/kg) and DFO (30 mg/
kg) were suspended in saline and injected locally into the 
tumor 5 days per week. The treatment was started 5 days 
after inoculation (n = 4). Control groups received PBS 
that was administered by local injection 5 days per week. 
The tumor volume was calculated by the formula: Length 
× Width × Height × 0.52. At the end of the experiment, 
the animals were sacrificed and the tumors were excised, 
weighed and further processed for histological analysis. 
These experiments were repeated 3 times.
Immunostaining analyses of excised tumors
The resected miPS-LLCcm tumors were fixed in 
10% paraformaldehyde and embedded in paraffin prior to 
immunostaining analysis. Anti-Nanog antibodies, anti-SOX2 
antibodies, anti-GFP antibodies, anti-c-Myc antibodies, and 
anti-Oct3/4 antibodies were purchased from Abcam as for 
western blot analysis. Pottasium Hexacyanoferrate (II) 
(catalog no. 28608–42) was purchased from Nacalai Tesque 
(Kyoto, Japan), and used for Berlin blue staining.
Statistical analysis
Data were compared against the respective control 
in each experiment using Student’s t test. Results were 
considered statistically significant when the P value was 
less than 0.05. Data analysis was performed using JMP 
ver.11 software (SAS, Cary NC27513).
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